Texas MPN Workshop 2022 | Recent advances in the treatment of BPDCN & the long-term benefits of tagraxofusp
Naveen Pemmaraju
• 27 Aug 2022
Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into advances that have been made in the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Dr Pemmaraju first highlights the importance of early diagnosis and intervention, and then goes on to explain the promising results observed with CD123-targeted therapies, including tagraxofusp and pivekimab sunirine. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
